Credits: Canva
Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.
The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.
The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.
The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.
The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.
The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.
Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."
The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.
However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.
Credit: iStock
In a major boost to India's fight against cervical cancer, the Indian Council of Medical Research (ICMR) has developed SHetA2, an indigenous drug candidate designed to treat HPV-induced cervical dysplasia and cervical cancer.
The novel anti-HPV therapeutic is being developed to treat Cervical Intraepithelial Neoplasia (CIN)— a precancerous condition caused by persistent human papillomavirus (HPV) infection— to prevent progression to invasive cervical cancer.
SHetA2 was developed through a collaboration between Dr. Showket Hussain of the ICMR-National Institute of Cancer Prevention and Research (ICMR-NICPR) and Dr. Doris M. Benbrook of the Stephenson Cancer Center, University of Oklahoma, USA.
It is a first-in-class targeted therapeutic candidate that selectively eliminates HPV-induced precancerous and cervical cancer cells while sparing healthy tissue. The technology has the potential to provide a safe, affordable and minimally invasive treatment option.
Under the Medical Innovations Patent Mitra (MITRA) initiative, ICMR has licensed SHetA2 to Emcure Pharmaceuticals Ltd.
SHetA2 is being evaluated for the treatment of HPV-induced cervical dysplasia and established cervical cancer. According to the ICMR, treating cervical dysplasia at the precancerous stage could significantly reduce the risk of progression to invasive cancer by enabling earlier intervention.
According to ICMR, SHetA2:
Read More: Affordable India-Made HPV Test Offers Hope For Early Cervical Cancer Detection
According to the Cleveland Clinic, cervical dysplasia is a precancerous condition caused by HPV infection in which abnormal cells develop on the surface of the cervix. It is also known as Cervical Intraepithelial Neoplasia (CIN).
Without treatment, cervical dysplasia can progress to cervical cancer. However, early detection and treatment can prevent abnormal cells from becoming cancerous.
The latest estimates show that annual cervical cancer cases in India have declined from approximately 1.27 lakh to around 79,000, marking a significant public health milestone in reducing the burden of one of the country's most common cancers among women.
Dr. Sandeep Nayak, Chairman of Oncology, MACS-Renova Oncology Institute, KIMS Hospital, said the development of SHetA2 is a major step toward indigenous innovation and self-reliance in India's fight against cervical cancer.
He noted that "for decades, pre-invasive conditions such as CIN or Stage 0 cervical carcinoma have been managed through surgical procedures including LEEP, laser ablation and cold knife conization. While effective, these treatments can affect cervical competence and future pregnancy outcomes in some women".
According to Dr. Nayak, SHetA2 represents a shift from surgical destruction to non-invasive medical management. As a potential oral or localized therapy, it could eliminate precancerous cells while preserving healthy tissue and cervical structure, an important advantage for younger women who wish to retain fertility.
He added that SHetA2 may also pave the way for targeted therapies against other HPV-associated diseases, including penile and anal intraepithelial neoplasia, as well as certain head and neck cancers.
Credit: AI
India continues to battle one of the world's highest burdens of preterm births. Early identification of critically ill newborns remains crucial for improving survival rates, particularly in hospitals with limited resources.
A new Indian study says that Clinical Risk Index for Babies-II (CRIB-II) score is an effective tool for predicting mortality risk among preterm newborns admitted to neonatal intensive care units (NICUs).
The research, conducted by doctors at JK Lone Hospital in Jaipur and published in the International Journal of Paediatric Research, can help preterm babies receive faster treatment and enable better use of neonatal intensive care resources.
The higher the score, the greater the risk of severe illness or death.
Researchers studied 181 premature newborns admitted to the tertiary care hospital. The babies had an average gestational age of 28.88 weeks and an average birth weight of 1.01 kg. The analysis showed a clear relationship between CRIB-II scores and outcomes:
Babies with higher CRIB-II scores were significantly more likely to die than those with lower scores, suggesting that the scoring system can accurately identify newborns requiring immediate intensive care.
Also read: Beyond The Bump: Why Preconceptions And Antenatal Care Are Key To A Healthy Pregnancy
Dr. Yogesh Yadav, paediatric specialist and one of the study's researchers, said the score enables doctors to make critical treatment decisions within the first few hours after admission.
"If we calculate the CRIB-II score at the time of admission, we can understand the seriousness of the baby's condition. This helps doctors decide the right treatment direction early and increases the chances of saving the baby."
He added that the score is more than simply a predictor of mortality. "CRIB-II is not just a score to predict death risk, but an important scientific tool for decision-making in the NICU. In the first few hours, we can identify which newborn is at high risk."
The researchers believe the scoring system could be particularly valuable across India, where NICUs often face shortages of beds, ventilators and trained neonatal staff.
According to Dr. Yadav: "When beds, ventilators or trained staff are limited, babies with higher scores can be given priority in the NICU. It also helps in deciding which newborns need to be referred immediately to higher centres."
The score can also improve communication with families by helping clinicians provide clearer information about a baby's condition and expected prognosis.
"Through CRIB-II, we can give parents a clearer and more accurate understanding of the baby's condition, possible outcomes and treatment needs."
Although CRIB-II has been used internationally for years, the latest Indian findings add to growing evidence supporting its use in neonatal intensive care.
Credit: AI
A newly identified brain protein may help slow the progression of Alzheimer's disease, according to new research that sheds light on how the disease spreads through the brain.
Scientists have found that a protein called SORLA acts as a natural defense against the toxic tau protein, limiting the brain damage that causes memory loss and cognitive decline.
The findings, published in Nature Neuroscience, suggest that boosting SORLA activity could become a therapeutic strategy.
The study found that SORLA regulates how tau proteins move between neurons. While amyloid plaques have long dominated Alzheimer's research, mounting evidence suggests that the spread of tau in the brain is more closely linked to the symptoms of Alzheimer's.
When SORLA levels were low, toxic tau spread more easily from one brain cell to another. In contrast, increasing SORLA significantly reduced tau accumulation, protected brain tissue from shrinking, and preserved memory in mouse models of Alzheimer's disease.
"Our findings identify SORLA as a potent endogenous suppressor of tau propagation," the researchers wrote, adding that enhancing SORLA function "could represent a promising therapeutic strategy for limiting the progression of Alzheimer's disease."
Also read: Alzheimer's Drug Leqembi Helps Over 75% Of Patients Remain Stable Or Improve: Real-World Study
Current Alzheimer's drugs like Leqembi primarily target amyloid-beta plaques. Although these treatments can slow disease progression in some patients, they do not directly stop the spread of tau, which drives the loss of brain cells which worsens dementia.
The discovery of SORLA offers a different approach by targeting one of the disease's most dangerous aspects: tau propagation.
The SORLA findings were demonstrated primarily in laboratory models, meaning much more research is needed before therapies can be tested in people.
However, researchers say identifying the brain's own protective mechanisms provides an important roadmap for developing treatments that not only remove harmful proteins but also prevent them from spreading.
If future studies confirm these findings in humans, therapies that boost SORLA could potentially be combined with existing anti-amyloid medicines to slow Alzheimer's progression more effectively.
The SORLA discovery comes amid growing momentum in tau-based Alzheimer's research.
Just this month, researchers reported encouraging results from diranersen, an experimental therapy designed to reduce production of the tau protein itself.
In a mid-stage clinical trial involving around 400 people with early Alzheimer's disease, the drug lowered tau levels and showed signs of slowing cognitive decline in some participants, although larger studies are needed to confirm its effectiveness.
Also read: Excessive TV Watching In Midlife May Shrink Brain Areas Essential For Memory, Study Finds
SORLA (Sorting Protein-Related Receptor with LDLR Class A Repeats) is a receptor protein naturally present in brain cells.
Scientists have known for years that low SORLA levels are associated with an increased risk of Alzheimer's disease because the protein helps process amyloid precursor protein.
Tau is a normal protein that helps stabilize the internal structure of nerve cells. In Alzheimer's disease, however, tau becomes abnormally folded and forms neurofibrillary tangles.
These tangles spread through interconnected brain regions, disrupting communication between neurons, and eventually causing them to die.
Researchers believe the progression of tau pathology closely mirrors the progression of memory loss and cognitive impairment seen in Alzheimer's patients.
© 2024 Bennett, Coleman & Company Limited